Posts

Sanofi halts eczema development of Kymab-originated OX40L antibody amlitelimab due to lack of meaningful clinical advantage and safety concerns

on

Sanofi's Bispecific Scores Double Respiratory Phase 2 Wins but Flunks Eczema Study

on

Sanofi Reports Positive but Mixed Phase 3 Results for Amlitelimab in Atopic Dermatitis with OX40L Targeting and Kaposi's Sarcoma Case

on

Sanofi's Amlitelimab Shows Mixed Phase 3 Results in Eczema Trials, Clouds Blockbuster Hopes but Advances to Regulatory Filings

on

Sanofi Phase 3 Eczema Win Falls Short of Analyst Expectations

on

Sanofis $1.4B Kymab Bet Falters as Asthma Drug Stumbles in Phase II

on

Sanofi tempers its OX40 expectations in asthma after mid-stage miss

on